Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil + Irinotecan/Temozolomide in Ewing's Sarcoma
NCT03495921Phase 3Terminated
- Sponsor
- Gradalis, Inc.
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemogenovatucel-T in Ewing sarcoma (2 arms), sponsored by Gradalis, Inc. Primary endpoint: Progression Free Survival at 3 years. Started Aug 2018; status: terminated.
02
Drugs
gemogenovatucel-T
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT03495921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495921.